Intracranial Hemorrhage Mortality in Atrial Fibrillation Patients Treated With Dabigatran or Warfarin | Zendy

Álvaro Alonso | Zendy; Lindsay G.S. Bengtson | Zendy; Richard F. MacLehose | Zendy; Pamela L. Lutsey | Zendy; Lin Y. Chen | Zendy; Kamakshi Lakshminarayan | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Intracranial Hemorrhage Mortality in Atrial Fibrillation Patients Treated With Dabigatran or Warfarin

Author(s) -

Álvaro Alonso,

Lindsay G.S. Bengtson,

Richard F. MacLehose,

Pamela L. Lutsey,

Lin Y. Chen,

Kamakshi Lakshminarayan

Publication year - 2014

Publication title -

stroke

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.397

H-Index - 319

eISSN - 1524-4628

pISSN - 0039-2499

DOI - 10.1161/strokeaha.114.006016

Subject(s) - medicine , dabigatran , atrial fibrillation , warfarin , stroke (engine) , cardiology , intracranial hemorrhages , intracerebral hemorrhage , subarachnoid hemorrhage , mechanical engineering , engineering

In randomized trials, patients with atrial fibrillation (AF) receiving dabigatran, a direct oral anticoagulant, had lower risk of intracranial bleeding (ICB) than those on warfarin. However, concerns exist about potential worse outcomes in dabigatran users if bleeding occurs, given the lack of approved reversal agents. Thus, we examined in-hospital mortality in AF patients with ICB being treated with dabigatran versus warfarin in a real-world population in the United States.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research